RESUMO
INTRODUCTION: The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and evolution of GUC patients affected by COVID-19 in Spain. PATIENTS AND METHODS: SOGUG-COVID-19 was an observational ambispective non-interventional study that recruited patients with SARS-CoV-2 infection who had been treated for GUC in 32 Spanish hospitals. Data were collected from patients' medical records in a short period of time, coinciding with the first waves of COVID-19, when the mortality was also higher in the general population. RESULTS: From November 2020 to April 2021, 408 patients were enrolled in the study. The median age was 70 years, and 357 patients (87.5%) were male. Most frequent Cancer Origin was: prostate (40.7%), urothelial (31.4%) and kidney (22.1%). Most patients (71.3%) were diagnosed at the metastatic stage, and 33.3% had poorly differentiated histology. Anticancer treatment during the infection was reported in 58.3% of patients, and 21.3% had received immunotherapy prior to or concurrent with the infection. The most frequent COVID-19 symptoms were pyrexia (49.0%), cough (38.2%) and dyspnea (31.9%). Median age was higher for patients with pneumonia (p < 0.001), patchy infiltrates (p = 0.005), ICU admission (p < 0.001) and death (p < 0.001). Tumor stage was associated with complications (p = 0.006). The fatality rate was 19.9% and the 6-month COVID-19-specific survival rate was 79.7%. CONCLUSION: Patients with genitourinary cancers seem exceptionally vulnerable to COVID-19 regardless of tumor type or anticancer therapy. Age and tumor stage were the only identified risk factors for severe COVID-19.
RESUMO
PURPOSE: Genitourinary (GU) multidisciplinary tumour boards (GUMTBs) are key components of patient care, as they might lead to changes in treatment plan, improved survival, and increased adherence to guidelines. However, there are no guidelines on how GUMTBs should operate or how to assess their quality of performance. METHODS: A systematic literature review was conducted to identify criteria and indicators to evaluate quality in GUMTBs. A scientific committee-comprising 12 GU cancer specialists from seven disciplines-proposed a list of criteria and developed indicators, evaluated in two rounds of Delphi method. Appropriateness and utility of indicators were scored using a 9-point Likert scale. Consensus was defined as at least two-thirds of Delphi respondents selecting a score sub-category that encompassed the median score of the group. RESULTS: Forty-five criteria were selected to evaluate the quality of GUMTBs covering five dimensions: organisation, personnel, protocol and documentation, resources, and interaction with patients. Then, 33 indicators were developed and evaluated in the first round of Delphi, leading to a selection of 26 indicators in two dimensions: function, governance and resources, and GUMTB sessions. In the second round, consensus was reached on the appropriateness of all 26 indicators and on the utility of 24 of them. Index cards for criteria and indicators were developed to be used in clinical practice. CONCLUSIONS: Criteria and indicators were developed to evaluate the quality of GUMTBs, aiming to serve as a guide to improve quality of care and health outcomes in patients with GU cancer.
Assuntos
Técnica Delphi , Indicadores de Qualidade em Assistência à Saúde , Neoplasias Urogenitais , Humanos , Neoplasias Urogenitais/terapia , Qualidade da Assistência à Saúde , Equipe de Assistência ao Paciente/normas , Consenso , Oncologia/normasRESUMO
RESUMEN El objetivo del presente trabajo es actualizar el análisis de los egresos hospitalarios (EH) por cáncer genitourinario (CGU), específicamente cáncer de próstata, testículo, vejiga y riñón en nuestro país. Para estos efectos se obtuvieron os datos del Boletín de Egresos Hospitalarios del Ministerio de Salud (MINSAL) del año 2010 y 2015, utilizándose los códigos de la clasificación internacional de enfermedades de la Organización Mundial de la Salud (OMS CIE-10). Los distintos diagnósticos fueron caracterizados según su composición geográfica y demográfica, comparándose con la información publicada en los reportes anteriores.(AU)
ABSTRACT The aim of the study is to update the analysis of hospital discharges for genitourinary cancer, specifically prostatic, testicular, bladder and renal cancers in our country. For this purpose, data was obtained from the registers of the Chilean Ministry of Health (MINSAL) for the years 2010 and 2015, using the international classification codes of diseases from the World Health Organization (WHO ICD-10). The different diagnoses were characterized according to their geographic and demographic distribution, comparing them to the information published in the previous reports.(AU)
Assuntos
Alta do Paciente , Neoplasias Urogenitais , ChileRESUMO
El objetivo del presente trabajo fue actualizar el análisis de los egresos hospitalarios (EH) de cáncer genitourinario (CGU), específicamente cáncer de próstata, testículo, vejiga y riñón, en nuestro país. Para estos efectos se obtuvieron los datos del boletín de egresos hospitalarios del Ministerio de Salud (MINSAL) del año 2005, utilizándose los códigos de la clasificación internacional de enfermedades de la OMS (CIE-10). Los distintos diagnósticos fueron caracterizados según su composición geográfica y demográfica, comparándose con la información publicada en los reportes anteriores. La proporción de patología oncológica genitourinaria dentro de los egresos hospitalarios por patología genitourinaria ha experimentado un alza sostenida, correspondiendo 10,9 por ciento a cáncer de próstata, 4,28 por ciento a cáncer de testículo, 3,92 por ciento a cáncer de vejiga, y 2,2 por ciento a cáncer renal. El presente reporte constituye una aproximación a nuestro quehacer como urólogos en nuestro país, y al mismo tiempo grafica la necesidad de crear herramientas de registro epidemiológico más efectivas.
The aim of the study was to update the analysis of hospital discharges because of genitourinary cancer in our country. For these purposes, data were obtained from the registers of the Chilean Ministry of Health. Diseases were codified according to the WHO ICD-10 classification. Hospital discharges because of genitourinary cancer has shown a steady increase since 1993.According to the last register (2005), 10.9 percent corresponds to prostate cancer, 4.28 percent to testicular cancer,3.92 percent to bladder cancer and 2.2 percent to renal cell cancer. The present analysis is a rough estimation of our activity in urological oncology. However, more accurate epidemiological tools are needed.